Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Withdrawn 1Recruiting 1No longer available 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 6Thyroid Carcinoma, Anaplastic 1Skin Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Petrolatum 2Fluorouracil 2trametinib 1talimogene laherparepvec 1sargramostim 1reolysin 1pimonidazole 1pembrolizumab 1fluoromisonidazole 1dabrafenib 1Trimethoprim, Sulfamethoxazole Drug Combination 1Surgical Procedures, Operative 1Sugars 1Radiotherapy 1Radiation 1Povidone-Iodine 1Melphalan 1Granulocyte-Macrophage Colony-Stimulating Factor 1Erlotinib Hydrochloride 1Clindamycin 1Clarithromycin 1Cephalexin 1Azithromycin 1Anti-Bacterial Agents 1Amoxicillin 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Skin Neoplasms × dabrafenib × Clear all
NCT03972046 2020-10-19

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

TriHealth Inc.

Phase 2 Withdrawn
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡